Top Markets
Coin of the day
CinCor Pharma, Inc. CinCor Pharma, Inc.

CinCor Pharma, Inc.

CINC
Rang in Aktien #11593
CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical... CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders. Additionally, CIN-107 is in Phase I clinical evaluation for its potential in treating chronic kidney diseases. The company holds a significant licensing agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. Established in 2018, CinCor Pharma, Inc. maintains its principal operations in Boston, Massachusetts.
Aktienkurs
$29.06
Zuletzt synchronisiert: 2023-02-23
Marktkapitalisierung
$682.73M
Veränderung (1 Tag)
-0.48%
Veränderung (1 Jahr)
0.00%
Land
US
Handel CinCor Pharma, Inc. (CINC)

Kategorie

Dividendenrendite-Verlauf für CinCor Pharma, Inc. (CINC)
Dividendenrendite (TTM) von CinCor Pharma, Inc. (Aktienkürzel: CINC) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für CinCor Pharma, Inc. (CINC) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH